<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564053</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA043A11101</org_study_id>
    <nct_id>NCT04564053</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants</brief_title>
  <official_title>A Randomized, Participant and Investigator Blinded, Placebo Controlled, Single Ascending Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Participants Wit Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to determine the safety, tolerability and pharmacokinetics&#xD;
      after single ascending dose of LNA043 in Japanese participants with osteoarthritis of the&#xD;
      knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a non-confirmatory, randomized, participant- and investigator-blinded,&#xD;
      placebo-controlled, single ascending dose study to investigate the safety, tolerability and&#xD;
      PK of LNA043 in Japanese participants with osteoarthritis of the knee. This study consisted&#xD;
      of 2 cohorts with a total of 12 participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a non-confirmatory, randomized, participant- and investigator-blinded, placebo-controlled, single ascending dose study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>To assess the safety and tolerability of single intra-articular injection of LNA043 in Japanese participants with osteoarthritis of the knee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve of LNA043 from zero to the last measurable concentration</measure>
    <time_frame>0 (pre-dose), 0.25, 2, 4, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>To assess systemic PK of LNA043 following single intra-articular injection of LNA043 in Japanese participants with osteoarthritis of the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum serum concentration of LNA043</measure>
    <time_frame>0 (pre-dose), 0.25, 2, 4, 8, 12, 24, 36, 48, 72, 168 hours post-dose</time_frame>
    <description>To assess systemic PK of LNA043 following single intra-articular injection of LNA043 in Japanese participants with osteoarthritis of the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-LNA043 antibodies in serum</measure>
    <time_frame>Day 1 (pre-dose), 4, 8, 15, 22</time_frame>
    <description>To assess systemic immunogenicity of LNA043 (anti-LNA043 antibodies) following single intra-articular injection of LNA043 in Japanese participants with osteoarthritis of the knee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Knee</condition>
  <arm_group>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LNA043</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNA043</intervention_name>
    <description>Single intra-articular injection on Day 1</description>
    <arm_group_label>LNA043</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intra-articular injection on Day 1</description>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female Japanese participants aged 20 to 80 years at screening&#xD;
&#xD;
          -  A body mass index (BMI) 16.0 kg/m2 or more but less than 35.0 kg/m2 at screening&#xD;
&#xD;
          -  Established diagnosis of primary tibio-femoral osteoarthritis of the target knee by&#xD;
             standard American College of Rheumatology (ACR) criteria for at least 6 months prior&#xD;
             to screening (clinical and radiological criteria).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Partial or complete joint replacement in the target knee. Planned knee surgery for&#xD;
             either knee during the study.&#xD;
&#xD;
          -  Arthroscopy of the target knee within 6 months prior to Screening or planned during&#xD;
             the study&#xD;
&#xD;
          -  Use of electrotherapy, acupuncture, and/or chiropractic treatments for osteoarthritis&#xD;
             of the knee within 4 weeks prior to screening&#xD;
&#xD;
          -  Malalignment &gt;10Â° in the target knee (varus/valgus)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>cartilage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

